Abstract:Key PointsCell-free DNA (cfDNA) is released predominantly by cell death into the bloodstream, although active secretion may have a role. Since the discovery of fetal cfDNA in the maternal circulation, cfDNA analysis has been rapidly implemented in clinical practice for noninvasive prenatal testing.Mutations were first detected in cfDNA more than two decades ago, and interest in circulating tumour DNA (ctDNA) as a noninvasive cancer diagnostic has increased considerably with the development of molecular methods that permit the sensitive detection and monitoring of multiple classes of mutation.ctDNA may have utility at almost every stage of the management of patients with cancer, including diagnosis, minimally invasive molecular profiling, treatment monitoring, the detection of residual disease and the identification of resistance mutations. ctDNA analysis may be broadly considered as a tool both for quantitative analysis of disease burden and for genomic analysis.The identification of ctDNA in individuals before a cancer diagnosis, and in presymptomatic individuals, suggests the possibility of ctDNA analysis as a tool for earlier detection and screening. Noninvasive cancer classification or subtyping has also emerged as a possibility, although for early detection, both technical and biological factors introduce challenges to the detection of mutant DNA in plasma and its interpretation.Monitoring multiple mutations in parallel can enhance the sensitivity of ctDNA detection, can be used to assess the clonal evolution of patients' disease and may identify resistance mutations before clinical progression is observed.ctDNA analysis is beginning to transition from the research setting into the clinic. The US Food and Drug Administration and the European Medicines Agency have approved ctDNA tests for specific indications in the absence of evaluable tumour tissue. Analysis of gene panels in plasma has now become available as a potential clinical tool. Large studies are under way to establish the overall performance and clinical utility of such assays when a tumour biopsy is not available for analysis.Potential applications of ctDNA have been demonstrated by a number of proof-of-principle studies. Prospective clinical trials are beginning to assess the clinical utility of ctDNA analysis for molecular profiling and disease monitoring. The increasing acceptance of ctDNA is enabling the field to move from exploratory ctDNA studies towards clinical trials in which ctDNA guides decision-making.In order to fully exploit the potential utility of liquid biopsies, it is essential that the biology of cfDNA and ctDNA is explored further. The mechanisms of release and degradation, and the factors that affect the representation of ctDNA in plasma, are poorly understood. The nature of ctDNA will be clarified through both large, well-annotated clinical studies and in vivo studies in which variables can be controlled.

Current challenges and best practices for cell-free long RNA biomarker discovery

Liquid Biopsy Based on Cell-Free DNA and RNA

Current and Future Perspectives of Cell-Free DNA in Liquid Biopsy

Challenges and Prospects of Cell-Free DNA in Precision Oncology

Exosomal lncRNAs: the newest promising liquid biopsy

Liquid biopsy: a step forward towards precision medicine in urologic malignancies

The potential of circulating cell-free RNA in CNS tumor diagnosis and monitoring: A liquid biopsy approach

Cell‐free RNA for the Liquid Biopsy of Gastrointestinal Cancer

Nucleic acid liquid biopsies in cardiovascular disease: Cell-free RNA liquid biopsies in cardiovascular disease

Cell-free RNA Liquid Biopsy to Monitor Hematopoietic Stem Cell Transplantation

Liquid biopsies come of age: towards implementation of circulating tumour DNA

A review on cell-free RNA profiling: Insights into metabolic diseases and predictive value for bariatric surgery outcomes

Controversies in the Interpretation of Liquid Biopsy Data in Lymphoma

Liquid biopsy: current technology and clinical applications

Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer

Assessment of Circulating Nucleic Acids in Cancer: From Current Status to Future Perspectives and Potential Clinical Applications

Liquid biopsy: paving a new avenue for cancer research

Emerging Role of Circulating Cell-Free RNA as a Non-Invasive Biomarker for Hepatocellular Carcinoma

Using All Our Genomes: Blood-based Liquid Biopsies for the Early Detection of Cancer

Cell-Free RNA Sequencing from Biofluid Samples.

Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer